News

This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by

The post Aligos and Xiamen Amoytop sign deal for HBV therapy appeared first on Pharmaceutical Business review.

The agreement involves Daiichi Sankyo Research Institute Boston and aims to assess the use of Interna’s MNM technology as a delivery enhancer for therapeutic modalities. Interna’s MNM molecules

The post Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions appeared first on Pharmaceutical Business review.

The collaboration aims to bridge gaps between data generation and actionable insights in spatial proteomics, as multiplex technologies for imaging advance. Spatial proteomics platforms create intricate tissue data,

The post Nucleai and Sirona Dx to provide new proteomics solution for pharma companies appeared first on Pharmaceutical Business review.

This Phase Ib/II study will measure the tolerability, safety, and early clinical activity by combining Boehringer Ingelheim’s DLL3 / cluster of differentiation 3 (CD3) T-cell engager, obrixtamig, with

The post Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study appeared first on Pharmaceutical Business review.

The financing will support Adcendo’s ongoing advancement of its first-in-class and best-in-class ADC pipeline targeting cancers of high unmet medical need, including further clinical development of three main

The post Adcendo secures $75m in Series C funding for ADC development appeared first on Pharmaceutical Business review.

The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer. The therapy is anticipated to have a US Food and Drug Administration

The post Lilly to acquire CrossBridge Bio for up to $300m appeared first on Pharmaceutical Business review.

The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition. FSGS is

The post Travere Therapeutics gains FDA approval for sparsentan in FSGS appeared first on Pharmaceutical Business review.

The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy. The FDA has scheduled a decision date for 10 October 2026

The post MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority appeared first on Pharmaceutical Business review.

The decision affects Replimune’s lead product candidate, which is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response. During the IGNYTE trial,

The post FDA issues complete response letter to Replimune’s RP1 for melanoma appeared first on Pharmaceutical Business review.

Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix’s expertise in radiopharmaceutical platforms, global

The post Telix and Regeneron to co-develop radiopharmaceutical therapies appeared first on Pharmaceutical Business review.